Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 11 II, 2003, Pages 1213-1221

  Takimoto, Chris H ^b   Glover, Kira ^a   Huang, Xiaoke ^a   Hayes, Steven A ^a   Gallot, Lilia ^a   Quinn, Mary ^c   Jovanovic, Borko D ^a   Shapiro, Alla ^c   Hernandez, Leticia ^b   Goetz, Andrew ^b,c   Llorens, Victor ^b   Lieberman, Ronald ^c   Crowell, James A ^c   Poisson, Brett A ^a   Bergan, Raymond C ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Olson 8524 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENISTEIN; GONADORELIN AGONIST; ISOFLAVONE; ISOFLAVONE DERIVATIVE; PTI G 2535; PTI G 4660; TYROSINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER PREVENTION; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG MANUFACTURE; FEMALE; GOOD MANUFACTURING PRACTICE; HALF LIFE TIME; HUMAN; MALE; METABOLISM; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SOYBEAN; TOXICITY TESTING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHORYLATION; SOYBEANS; TYROSINE;

EID: 10744226314     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Adlercreutz, H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand. J. Clin. Lab. Investig. Suppl., 201: 3-23, 1990.
2. Severson, R. K., Nomura, A. M., Grove, J. S., and Stemmermann, G. N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res., 49: 1857-1860, 1989.
3. Shimizu, H., Ross, R. K., Bernstein, L., Yatani, R., Henderson, B. E., and Mack, T. M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer, 63: 963-966, 1991.
4. Cook, L. S., Goldoft, M., Schwartz, S. M., and Weiss, N. S. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol., 161: 152-155, 1999.
5. Liu, Y. U., Kyle, E., Lieberman, R., Crowell, J., Kelloff, G., and Bergan, R. C. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation. Clin. Exp. Metastasis, 18: 203-212, 2000.
6. Bergan, R., Kyle, E., Nguyen, P., Trepel, J., Ingui, C., and Neckers, L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to β-1-integrin. Clin. Exp. Metastasis, 14: 389-398, 1996.
7. Kyle, E., Neckers, L., Takimoto, C., Curt, G., and Bergan, R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol., 51: 193-200, 1997.
8. Adlercreutz, H., Markkanen, H., and Watanabe, S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet, 342: 1209-1210, 1993.
9. Liu, Y. Q., Kyle, E., Patel, S., Housseau, F., Hakim, F., Lieberman, R., Pins, M., Blagosklonny, M., and Bergan, C. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic, Dis, 4: 81-91, 2001.
10. Wang, H. K. The therapeutic potential of flavonoids. Expert Opin. Investig. Drugs, 9: 2103-2119, 2000.
11. Beck, V., Unterrieder, E., Krenn, L., Kubelka, W., and Jungbauer, A. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J. Steroid Biochem. Mol. Biol., 84: 259-268, 2003.
12. Chen, C. C., Shieh, B., Jin, Y. T., Liau, Y. E., Huang, C. H., Liou, J. T., Wu, L. W., Huang, W., Young, K. C., Lai, M. D., Liu, H. S., and Li, C. Microarray profiling of gene expression patterns in bladder tumor cells treated with genistein. J. Biomed. Sci., 8: 214-222, 2001.
13. Jovanovic, B. D., Huang, S., Liu, Y., Naguib, K. N., and Bergan, R. C. An analysis of gene array data related to cell adhesion and prostate cancer. Cancer Treat. Res., 133: 91-111, 2002.
14. Li, Y., and Sarkar, F. H. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J. Nutr., 132: 3623-3631, 2002.
15. Hackett, A. M. The metabolism of flavonoid compounds in mammals. Prog. Clin. Biol. Res., 213: 177-194, 1986.
16. Supko, J. G., and Phillips, L. R. High-performance liquid chromatographic assay for genistein in biological fluids. J. Chromatogr. B Biomed. Appl., 666: 157-167, 1995.
17. Xu, X., Harris, K. S., Wang, H. J., Murphy, P. A., and Hendrich, S. Bioavailability of soybean isoflavones depends upon gut microflora in women. J. Nutr., 125: 2307-2315, 1995.
18. Watanabe, S., Yamaguchi, M., Sobue, T., Takahashi, T., Miura, T., Arai, Y., Mazur, W., Wahala, K., and Adlercreutz, H. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J. Nutr., 128: 1710-1715, 1998.
19. Busby, M. G., Jeffcoat, A. R., Bloedon, L. T., Koch, M. A., Black, T., Dix, K. J., Heizer, W. D., Thomas, B. F., Hill, J. M., Crowell, J. A., and Zeisel, S. H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr., 75: 126-136, 2002.
20. Bloedon, L. T., Jeffcoat, A. R., Lopaczynski, W., Schell, M. J., Black, T. M., Dix, K. J., Thomas, B. F., Albright, C., Busby, M. G., Crowell, J. A., and Zeisel, S. H. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am. J. Clin. Nutr., 76: 1126-1137, 2002.
21. Takimoto, C. H. Basic pharmacokinetics and pharmacodynamic principals. In: R. C. Bergan (ed.), Cancer Chemoprevention, pp. 85-102. Boston: Kluwer Academic Publishers, 2001.
22. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
23. Thomas, B. F., Zeisel, S. H., Busby, M. G., Hill, J. M., Mitchell, R. A., Scheffler, N. M., Brown, S. S., Bloeden, L. T., Dix, K. J., and Jeffcoat, A. R. Quantitative analysis of the principle soy isoflavones genistein, daidzein and glycitein, and their primary conjugated metabolites in human plasma and urine using reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 760: 191-205, 2001.
24. Gibaldi, M., and Perrier, D. Pharmacokinetics. New York: Marcel Dekker, 1982.
25. Lam, F. C., Hung, C. T., and Perrier, D. G. Estimation of variance for harmonic mean half-lives. J. Pharm. Sci., 74: 229-231, 1985.
26. Robinson, J. D., Lupkiewicz, S. M., Palenik, L., Lopez, L. M., and Ariet, M. Determination of ideal body weight for drug dosage calculations. Am. J. Hosp. Pharm., 40: 1016-1019, 1983.
27. Schwartz, G. N., Liu, Y. Q., Tisdale, J., Walshe, K., Fowler, D., Gress, R., and Bergan, R. C. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity. Antisense Nucleic Acid Drug Dev., 8: 329-339, 1998.
28. Bergan, R., Hakim, F., Schwartz, G. N., Kyle, E., Cepada, R., Szabo, J. M., Fowler, D., Gress, R., and Neckers, L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood, 88: 731-741, 1996.
29. Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., Hamalainen, E., Hasegawa, T., and Okada, H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr., 54: 1093-1100, 1991.
30. Arai, Y., Watanabe, S., Kimira, M., Shimoi, K., Mochizuki, R., and Kinae, N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr., 130: 2243-2250, 2000.
31. Arai, Y., Uehara, M., Sato, Y., Kimira, M., Eboshida, A., Adlercreutz, H., and Watanabe, S. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J. Epidemiol., 10: 127-135, 2000.
32. Horiuchi, T., Onouchi, T., Takahashi, M., Ito, H., and Orimo, H. Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporos. Int., 11: 721-724, 2000.
33. Kimira, M., Arai, Y., Shimoi, K., and Watanabe, S. Japanese intake of flavonoids and isoflavonoids from foods. J. Epidemiol., 8: 168-175, 1998.
34. Nagata, C., Kabuto, M., Kurisu, Y., and Shimizu, H. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr. Cancer, 29: 228-233, 1997.
35. Nagata, C., Takatsuka, N., Kurisu, Y., and Shimizu, H. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J. Nutr., 128: 209-213, 1998.
36. Nagata, C., Inaba, S., Kawakami, N., Kakizoe, T., and Shimizu, H. Inverse association of soy product intake with serum androgen and estrogen concentrations in Japanese men. Nutr. Cancer, 36: 14-18, 2000.
37. Nagata, C., Shimizu, H., Takami, R., Hayashi, M., Takeda, N., and Yasuda, K. Relations of insulin resistance and serum concentrations of estradiol and sex hormone-binding globulin to potential breast cancer risk factors. Jpn. J. Cancer Res., 91: 948-953, 2000.
38. Nagata, C., Takatsuka, N., Kawakami, N., and Shimizu, H. Association of diet with the onset of menopause in Japanese women. Am. J. Epidemiol., 152: 863-867, 2000.
39. Takatsuka, N., Nagata, C., Kurisu, Y., Inaba, S., Kawakami, N., and Shimizu, H. Hypocholesterolemic effect of soymilk supplementation with usual diet in premenopausal normolipidemic Japanese women. Prev. Med., 31: 308-314, 2000.
40. Wakai, K., Egami, I., Kato, K., Kawamura, T., Tamakoshi, A., Lin, Y., Nakayama, T., Wada, M., and Ohno, Y. Dietary intake and sources of isoflavones among Japanese. Nutr. Cancer, 33: 139-145, 1999.
41. Yamamoto, S., Sobue, T., Sasaki, S., Kobayashi, M., Arai, Y., Uehara, M., Adlercreutz, H., Watanabe, S., Takahashi, T., Iitoi, Y., Iwase, Y., Akabane, M., and Tsugane, S. Validity and reproducibility of a self-administered food-frequency questionnaire to assess isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J. Nutr., 131: 2741-2747, 2001.
42. Richardson, M. A., Sanders, T., Palmer, J. L., Greisinger, A., and Singletary, S. E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol., 18: 2505-2514, 2000.
43. Kao, G. D., and Devine, P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer (Phila.), 88: 615-619, 2000.
44. Nabhan, C., and Bergan, R. Chemoprevention in prostate cancer. In: R. C. Bergan (ed.), Cancer Chemoprevention, pp. 103-136. Boston: Kluwer Academic Publishers, 2001.
45. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med., 330: 1029-1035, 1994.
46. Bergan, R. C., Waggle, D. H., Carter, S. K., Horak, I., and Slichenmyer, W. Tyrosine kinase inhibitors and signal transduction modulators: rationale and current status as chemopreventive agents for prostate cancer. Urology, 57: 77-80, 2001.
47. Loos, W. J., Gelderblom, H., Sparreboom, A., Verweij, J., and de Jonge, M. J. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin. Cancer Res., 6: 2685-2689, 2000.
48. Mathijssen, R. H., Verweij, J., de Jonge, M. J., Nooter, K., Stoter, G., and Sparreboom, A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J. Clin. Oncol., 20: 81-87, 2002.
49. Sawyer, M., and Ratain, M. J. Body surface area as a determinant of pharmacokinetics and drug dosing. Investig. New Drugs, 19: 171-177, 2001.
50. Rowland, I. R., Wiseman, H., Sanders, T. A., Adlercreutz, H., and Bowey, E. A. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr. Cancer, 36: 27-32, 2000.
51. Committee on Diet, Nutrition, and Cancer, Assembly of Life Sciences, National Research Council. Diet, Nutrition and Cancer. Washington, DC: National Academy Press, 1982.